TAM Receptor

TAM receptor inhibitors act on Tyro3, Axl and Mer, three receptor tyrosine kinases in immune control. Axl was described in 1991 as a transforming gene isolated from primary human myeloid leukemia cells. The receptors bind the ligands growth arrest-specific 6 (Gas6) and protein S, and they mediate clearance of apoptotic cells by phagocytes. TAM signaling also limits inflammatory responses of dendritic cells and macrophages, as reviewed in 2008. R428 and dubermatinib are Axl inhibitors, whereas UNC569 targets Mer and LDC1267 acts on all three family members. Cabozantinib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and the hepatocyte growth factor receptor (c-Met), also inhibits Axl.

Items 26-50 of 64

  • UNC1062
    Cat. No.
    A25897

    UNC1062

    UNC1062 is a selective inhibitor of the MERTK tyrosine kinase, exhibiting an IC50 of 1.1 nM and strong selectivity within the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). It displays significant anti-proliferative effects and induces apoptosis across various cancer models, including melanoma, gastric cancer, and acute myeloid leukemia. UNC1062 modulates key signaling pathways such as MAPK/ERK, PI3K/AKT, and JAK/STAT, while also impacting cellular motility in head and neck squamous cell carcinoma through the RhoA pathway. Additionally, it inhibits macrophage efferocytosis, making it a valuable tool for research in atherosclerosis.

    1 mg
    $70.00
    5 mg
    $140.00
    All 7 sizes
  • Batiraxcept
    Cat. No.
    A25991

    Batiraxcept

    Synonyms: AVB-500; AVB-S6-500

    Batiraxcept is a selective inhibitor of the AXL receptor and GAS6, targeting the GAS6-AXL signaling pathway. With a high affinity for GAS6 (KD

    1 mg
    $480.00
    5 mg
    $1,230.00
    All 3 sizes
  • Axl-IN-18
    Cat. No.
    A32096

    Axl-IN-18

    Axl-IN-18 is a selective type II inhibitor of AXL, demonstrating potent inhibitory activity with an IC50 of 1.1 nM and a remarkable 343-fold selectivity over the closely related kinase MET (IC50=377 nM). This compound effectively hinders AXL-mediated cell proliferation, reduces cell migration and invasion in a dose-dependent manner, and triggers apoptosis. Axl-IN-18 exhibits significant antitumor efficacy in a BaF3/TEL-AXL xenograft model, making it a valuable tool for research into AXL-related cancer pathways and therapeutic interventions.

    Out of stock

    All 3 sizes
  • UNC5293
    Cat. No.
    A33661

    UNC5293

    UNC5293 is a potent and selective inhibitor of MERTK, with a Ki of 190 pM and an IC50 of 0.9 nM. It demonstrates a superior selectivity compared to Axl, Tyro3, and Flt3, making it an essential tool for studying MERTK-related pathways. Additionally, UNC5293 possesses favorable pharmacokinetic properties in mouse models, supporting its application in research on bone marrow leukemia and related hematological disorders.

    5 mg
    $160.00
    10 mg
    $255.00
    All 5 sizes
  • UNC4203
    Cat. No.
    A33666

    UNC4203

    UNC4203 is a highly selective MERTK inhibitor that exhibits potent inhibitory activity, with an IC50 of 1.2 nM against MERTK and has significantly lower inhibition against related kinases, including IC50s of 140 nM for AXL, 42 nM for TYRO3, and 90 nM for FLT3. Due to its oral bioavailability and selectivity, UNC4203 is a valuable tool for investigating the role of MERTK in various biological processes. Its potential applications include cancer research and therapeutic development targeting MERTK-related signaling pathways.

    5 mg
    $115.00
    10 mg
    $190.00
    All 5 sizes
  • AXL-IN-13
    Cat. No.
    A33673

    AXL-IN-13

    AXL-IN-13 is a potent and orally bioavailable inhibitor of AXL, exhibiting an IC50 of 1.6 nM and a Kd of 0.26 nM. This compound effectively reverses TGF-β1-induced epithelial-mesenchymal transition (EMT) and demonstrates significant inhibition of cancer cell migration and invasion. AXL-IN-13 serves as a valuable tool for studying the role of AXL signaling in cancer progression and metastasis.

    1 mg
    $65.00
    5 mg
    $155.00
    All 7 sizes
  • Protein kinase inhibitor 10
    Cat. No.
    A34293

    Protein kinase inhibitor 10

    Protein Kinase Inhibitor 10 is a potent protein kinase inhibitor targeting TAM receptors, FAK, and KIT with IC50 values of 28.9, 13.6, and 2.41 μM, respectively. This compound effectively inhibits abnormal and excessive cell proliferation, making it a valuable tool for research in cancer therapy. Its specificity and potency render it suitable for studying cellular signaling pathways associated with oncogenesis and for potential therapeutic applications in cancer treatment.

    1 mg
    $45.00
    5 mg
    $140.00
    All 6 sizes
  • Axl-IN-8
    Cat. No.
    A34364

    Axl-IN-8

    Axl-IN-8 is a highly potent inhibitor of AXL, exhibiting an IC50 of less than 1 nM. This compound also targets c-MET, demonstrating inhibitory activity with an IC50 range of 1-10 nM. Axl-IN-8 displays significant anti-proliferative effects on various cancer cell lines, including BaF3/TEL-AXL, MKN45, and EBC-1, with IC50 values of less than 10 nM, 226.6 nM, and 120.3 nM, respectively. This makes Axl-IN-8 a valuable tool for research into AXL- and c-MET-related signaling pathways and potential therapeutic applications in cancer.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Axl-IN-21
    Cat. No.
    A44254

    Axl-IN-21

    Axl-IN-21 is a selective, orally active inhibitor targeting the AXL receptor tyrosine kinase with a Kd of 2.7 nM and an IC50 of 4.0 nM. It demonstrates significant kinase selectivity and exhibits potent activity against various cancer-related multikinases, including Mer (Kd = 1.4 nM) and DDR1 (IC50 = 22.2 nM). Axl-IN-21 effectively blocks GAS6-induced AXL/STAT3/ABCG1 signaling, which enhances chemosensitivity and mitigates drug efflux in gastric cancer. Furthermore, this compound inhibits TGF-β1-mediated epithelial-mesenchymal transition, migration, and invasion in MDA-MB-231 cells, while showing minimal cytotoxicity to non-cancerous cells, making it a promising candidate for research in triple-negative breast cancer and gastric cancer.

    Out of stock

    All 3 sizes
  • Axl-IN-20
    Cat. No.
    A84747

    Axl-IN-20

    Axl-IN-20 is a selective AXL inhibitor with a potent IC50 of 5 nM. This orally active compound demonstrates significant anti-tumor activity, particularly against hematological malignancies. It is a valuable tool for research applications aimed at understanding AXL signaling pathways and developing targeted cancer therapies.

    Out of stock

    All 3 sizes
  • TAM-IN-1
    Cat. No.
    A84748

    TAM-IN-1

    TAM-IN-1 is a potent macrocyclic inhibitor targeting TAM receptors Axl and Mer, displaying binding affinities with Kis of 130 pM and

    Out of stock

    All 3 sizes
  • UNC9426
    Cat. No.
    A84749

    UNC9426

    UNC9426 is a highly selective inhibitor of TYRO3, exhibiting an IC50 of 2.1 nM and demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. This compound effectively reduces platelet aggregation without prolonging bleeding time, and it inhibits TYRO3-mediated processes in both tumor cells and macrophages. With a favorable safety profile, UNC9426 is an invaluable tool for investigating TYRO3-dependent phenotypes, including applications in non-small cell lung cancer (NSCLC) research.

    1 mg
    $35.00
    5 mg
    $80.00
    All 6 sizes
  • Ligritinib
    Cat. No.
    A84750

    Ligritinib

    Synonyms: AB801

    Ligritinib is an AXL receptor tyrosine kinase inhibitor that displays oral bioavailability. It effectively inhibits AXL kinase activity, disrupting downstream signaling pathways associated with cancer progression. Ligritinib is particularly relevant in cancer research, and it is often investigated in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).

    5 mg
    $1,105.00
    10 mg
    $1,810.00
    All 4 sizes
  • BPR5K230
    Cat. No.
    A84751

    BPR5K230

    BPR5K230 is a dual inhibitor targeting the receptor tyrosine kinases MER and AXL, exhibiting IC50 values of 4.1 nM and 9.2 nM, respectively. This compound effectively inhibits the proliferation of Ba/F3-MER cells, with an IC50 of 5 nM. In preclinical models, BPR5K230 demonstrates anti-inflammatory and antitumor activities against various cancer cell lines, including 4T1, MDA-MB-231, MC38, and Hepa1-6, as well as favorable pharmacokinetic properties in mice. These attributes make BPR5K230 a valuable tool for research into cancer biology and targeted therapies.

    5 mg
    $485.00
    10 mg
    $830.00
    All 5 sizes
  • AZ14145845
    Cat. No.
    A84752

    AZ14145845

    AZ14145845 is a selective inhibitor targeting the TAM receptor kinases Mer and Axl, classified as a type I1/2 dual kinase inhibitor. This compound demonstrates notable in vivo efficacy, making it a valuable tool for research in cancer biology and therapeutic resistance mechanisms. Its selective inhibition of the TAM receptors contributes to the modulation of immune responses and potential enhancement of antitumor activity, serving as a significant asset in studies focused on cancer treatment and immunotherapy.

    5 mg
    $235.00
    10 mg
    $380.00
    All 5 sizes
  • TL4830031
    Cat. No.
    A84753

    TL4830031

    TL4830031 is a potent Axl inhibitor, exhibiting an IC50 value of 26 nM. This compound effectively disrupts Axl phosphorylation, leading to inhibition of cell invasion and migration. TL4830031 is an ideal reagent for cancer research applications, providing valuable insights into tumor biology and potential therapeutic interventions targeting the Axl pathway.

    1 mg
    $315.00
    5 mg
    $805.00
    All 3 sizes
  • Axl-IN-6
    Cat. No.
    A84754

    Axl-IN-6

    Axl-IN-6 is a potent AXL inhibitor that demonstrates significant anti-tumor activity. This orally active compound effectively inhibits tumor growth in the MV-4-11 subcutaneous xenograft model, showcasing its potential for cancer research applications. Axl-IN-6 is well tolerated, making it a suitable candidate for evaluating AXL targeting in therapeutic studies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • MerTK-IN-3
    Cat. No.
    A84755

    MerTK-IN-3

    MerTK-IN-3 is a selective MerTK inhibitor, demonstrating an IC50 of 21.5 nM for MerTK while maintaining a significantly higher IC50 of 991.3 nM for Tyro3. This compound is suitable for research applications focused on colon cancer, enabling studies into MerTK's role in tumor progression and potential therapeutic interventions. Its oral bioavailability further enhances its utility in preclinical studies.

    Out of stock

    All 3 sizes
  • Axl-IN-9
    Cat. No.
    A84756

    Axl-IN-9

    Axl-IN-9 is a potent inhibitor of AXL, exhibiting an IC50 of 26 nM. This compound demonstrates excellent transmembrane and pharmacokinetic properties, making it suitable for in vivo studies. Axl-IN-9 is intended for research applications in proliferative diseases, autoimmune disorders, allergic reactions, inflammatory conditions, transplant rejection, cancer, and other related mammalian diseases.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Axl-IN-11
    Cat. No.
    A84757

    Axl-IN-11

    Axl-IN-11 is a potent AXL inhibitor that targets the AXL receptor tyrosine kinase. It exhibits significant biological activity in the modulation of cell proliferation and migration, making it useful in the study of various proliferative and autoimmune diseases, as well as in cancer research. Additionally, Axl-IN-11 can be applied in the investigation of allergic, inflammatory, and viral infectious diseases, as well as transplant rejection mechanisms in mammals.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Axl-IN-4
    Cat. No.
    A84758

    Axl-IN-4

    Axl-IN-4 is an AXL kinase inhibitor that demonstrates an IC50 of 28.8 μM. This compound specifically targets the AXL receptor tyrosine kinase, which is implicated in multiple cancer pathways and immune responses. Axl-IN-4 is useful for research applications aiming to elucidate the roles of AXL in tumor progression and to explore potential therapeutic strategies against AXL-driven malignancies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Axl-IN-17
    Cat. No.
    A84759

    Axl-IN-17

    Axl-IN-17 is a selective AXL inhibitor that demonstrates potent inhibitory activity with an IC50 value of 3.2 nM. This compound exhibits significant antitumor efficacy, making it a valuable tool for research in cancer biology. Axl-IN-17 is suitable for studies focusing on AXL-mediated signaling pathways and their implications in tumor progression and metastasis.

    Out of stock

    All 3 sizes
  • Axl-IN-10
    Cat. No.
    A84760

    Axl-IN-10

    Axl-IN-10 is a potent AXL inhibitor with an IC50 of 5 nM, effectively targeting the AXL receptor. This compound exhibits favorable transmembrane and pharmacokinetic properties, enhancing its utility in biological research. Axl-IN-10 is applicable in the study of various proliferative diseases, autoimmune disorders, allergic reactions, inflammatory conditions, transplant rejection, and cancer, making it a valuable tool for researchers exploring these complex pathologies in mammals.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • UNC3133
    Cat. No.
    A84761

    UNC3133

    UNC3133 is a selective and orally bioavailable inhibitor of the Mer tyrosine kinase (MerTK), demonstrating an IC50 of 8.1 nM. This compound exhibits preferential inhibition of the TAM receptor family, particularly with approximately sevenfold selectivity for Axl and tenfold selectivity for Tyro3, while also showing comparable activity against Flt3. UNC3133 is applicable in research focused on anti-tumor and anti-infection mechanisms, providing insights into therapeutic strategies targeting these pathways.

    Out of stock

    All 3 sizes
  • Axl-IN-12
    Cat. No.
    A84762

    Axl-IN-12

    Axl-IN-12 is a potent AXL inhibitor that selectively targets the AXL receptor tyrosine kinase. It exhibits significant biological activity in regulating cell proliferation and modulating immune responses. Axl-IN-12 is suitable for research applications related to proliferative diseases, autoimmune disorders, allergic responses, inflammation, transplant rejection, various malignancies, and viral infections in mammalian systems.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

Items 26-50 of 64

Added to your cart

View Cart Checkout

    Loading...